# Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

> **NCT05933395** · PHASE2 · RECRUITING · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 135 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Neratinib
- **DRUG:** Alpelisib
- **DRUG:** Everolimus
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT05933395
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2030-10
- **Final completion:** 2031-10
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933395, "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05933395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*